Premium
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3‐ITD acute myeloid leukemia prior to stem cell transplant and after relapse post‐transplant
Author(s) -
Sammons Sarah L.,
Pratz Keith W.,
Smith B. Douglas,
Karp Judith E.,
Emadi Ashkan
Publication year - 2014
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23782
Subject(s) - sorafenib , myeloid leukemia , medicine , stem cell , oncology , leukemia , myeloid , fms like tyrosine kinase 3 , transplantation , cancer research , biology , gene , hepatocellular carcinoma , genetics , biochemistry , mutation
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom